This article was originally published on this site
The trading week got off to a stellar start Monday for biotech investorsThe Food and Drug Administration (FDA) granted approval to Biogen Inc.’s (BIIB) Alzheimer’s drug candidate aducanumab, which was a 50/50 proposition at best based on study dataThis seems to be a decision based more on pressure than approval criteriaThe drug is likely to a have…
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a subscriber? Please Login